What does an Allred score indicate about estrogen receptor status and its implications for endocrine therapy in breast cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Allred Scoring: Clinical Implications for Breast Cancer Management

The Allred score is a clinically validated immunohistochemical scoring system that predicts response to endocrine therapy in breast cancer by combining the proportion and intensity of estrogen receptor (ER) or progesterone receptor (PgR) positive tumor cells, with an Allred score ≥3 (corresponding to ≥1% positive cells) defining hormone receptor positivity and indicating potential benefit from endocrine therapy. 1

What the Allred Score Measures

The Allred scoring system combines two components:

  • Proportion Score (PS): Percentage of tumor cells with positive nuclear staining (0-5 scale)
  • Intensity Score (IS): Average staining intensity of positive cells (0-3 scale: weak, moderate, strong)
  • Total Score (TS): Sum of PS + IS, ranging from 0-8

The scoring is bimodal in nature, clearly distinguishing ER-negative from ER-positive cancers with high sensitivity (99.4%) and specificity (99.5%) 2.

Critical Clinical Thresholds

For ER Status:

  • Allred score ≥3 = Positive (corresponds to 1-10% weakly positive cells) 1
  • This is the validated cutoff for considering endocrine therapy
  • Scores of 0-2 are considered negative

For PgR Status:

  • Allred score >2 = Positive (corresponds to >1% positive cells) 1
  • Best cutoff for both disease-free survival (P=0.0021) and overall survival (P=0.0014) in patients receiving adjuvant endocrine therapy 1

Predictive Value for Treatment Response

The Allred score directly predicts clinical outcomes:

Response to Endocrine Therapy:

  • Significant correlation exists between ER levels by Allred score and response rates 1
  • ER-negative (Allred 0-2): 25% response rate
  • ER-intermediate: 46% response rate
  • ER-high: 66% response rate 1

Time to Treatment Failure:

  • ER-negative: 5 months median
  • ER-intermediate: 4 months median
  • ER-high: 10 months median 1

Survival Outcomes: Higher Allred scores correlate with improved overall survival, disease-free survival, recurrence-free survival, and time to recurrence 1.

The Low-Positive Category (Allred Score 3)

This is a critical clinical caveat. Tumors with Allred scores of 3 (1-10% weakly positive cells) represent a heterogeneous group with distinct characteristics 3:

  • Often have molecular profiles more similar to ER-negative cancers
  • Show more limited clinical benefit data compared to higher ER expressers
  • Should be reported as "ER Low Positive" with explanatory comments 3

However, endocrine therapy should still be considered because:

  • Even low ER levels (1-10%) show significant clinical response in multiple studies 1
  • Endocrine therapy has relatively low toxicity
  • The 2011 meta-analysis of >200,000 women-years showed patients with low ER levels (10-20 fmol/mg by ligand-binding assay, roughly equivalent to 1-10% by IHC) had recurrence risk reduced by one-third with tamoxifen (RR 0.67) 3

For patients with Allred score 3, discuss both the potential benefits and the more limited evidence base, then make an informed decision based on the complete clinical picture 1, 3.

Prognostic Information Beyond Treatment Selection

The percentage of positive cells provides valuable prognostic stratification:

  • Higher receptor levels = better outcomes across multiple endpoints 1
  • This relationship holds for both ER and PgR
  • The proportional benefit of endocrine therapy increases somewhat with higher ER levels, though even weakly positive tumors benefit 3

Validation and Quality Assurance

The Allred scoring system is one of the well-validated assays listed in ASCO/CAP guidelines 1. Laboratories must:

  • Achieve 90% concordance with clinically validated assays for positive cases
  • Achieve 95% concordance for negative cases 1
  • Report both percentage and intensity, not just the final interpretation 1

Comparison with Other Scoring Methods

While H-score and percentage-only methods exist, the Allred score has specific advantages:

  • Bimodal distribution clearly separates positive from negative 2
  • Reduces "weak positive" cases from 18% to 5% compared to conventional scoring 2
  • Excellent correlation with clinical outcomes in multiple validation studies 1, 4, 5
  • The proportion score alone may be sufficient for prediction, but intensity adds quality control 4, 5

References

Related Questions

What is the significance of the Allred scoring system in assessing hormone receptor status in breast cancer tissues?
What does an estrogen receptor (ER) Allred score of 4 out of 8 indicate?
How should estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status be assessed and used to guide treatment in breast cancer?
Which fluoroquinolone eye drop should be used for bacterial conjunctivitis?
What is the appropriate anticoagulation regimen for a nursing‑home resident in their late 80s with anemia who has a non‑occlusive deep vein thrombosis (DVT) of the right popliteal vein?
After a tooth extraction, should I brush my teeth before or after using the LR (Listerine) mouth rinse?
Is it appropriate to use salmeterol as both a maintenance (long‑acting) and rescue inhaler in a 13‑year‑old patient?
What dose range of melatonin is effective for reducing sleep latency in adults?
What is the appropriate management for a 37‑year‑old woman with a one‑week history of eyelid swelling, watery and blurry vision, who has been using oral loratadine (Claritin) and erythromycin ophthalmic ointment with partial improvement but persistent eye ache?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.